VESSEL DUE F Capsules

VESSEL DUE F Capsules contain 250 LSU of Sulodexide

Vessel Due F contains Sulodexide glycosaminoglycan featuring a marked antithrombotic action either on arterial or venous systems. Several clinical studies based on parenteral and oral product administration show that the antithrombotic action of Sulodexide is due to the dose-dependent inhibition of some coagulative factors among which, first of all, the Xactivated factor, interference with thrombin remains instead at levels of low significance and the consequences of a coagulative action are generally avoided.

Antithrombotic action is sustained even by the inhibition of platelet aggregation and by the activation of circulatory and wall fibrinolytic systems.

Sulodexide is also capable of normalizing altered viscosimetric parameters generally present in patients with vascular pathologies with thrombotic risk; this action mainly relies on reduced fibrinogen values.

Full Product Information

Back

FEATURED

Articles

Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial

Treatment of COVID-19 patients with sulodexide, when provided within 3 days of clinical onset, improved their clinical outcomes. Although the results should be confirmed, sulodexide could be valuable in an outpatient setting.

Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis

Micro- and macrovascular complications of diabetes are leading morbidities in the world population. They are responsible not only for increased mortality but also severe disabilities, which jeopardize quality of life (e.g., blindness, walking limitations, and renal failure requiring dialysis).

Endothelial Glycocalyx as a Regulator of Fibrotic Processes

The endothelial glycocalyx, the gel layer covering the endothelium, is composed of glycosaminoglycans, proteoglycans, and adsorbed plasma proteins. This structure modulates vessels’ mechanotransduction, vascular permeability, and leukocyte adhesion. Thus, it regulates several physiological and pathological events. In the present review, we described the mechanisms that disturb glycocalyx stability such as reactive oxygen species, matrix metalloproteinases, and heparanase. We then focused our attention on the role of glycocalyx degradation in the induction of profibrotic events and on the possible pharmacological strategies to preserve this delicate structure. In this situation, a promising agent is sulodexide, a mixture of 80% fast-moving heparin and 20% of dermatan sulfate. Sulodexide has antithrombotic, profibrinolytic, anti-inflammatory, antioxidant, and anti-ischemic properties. In addition, its proposed mode of action is the inhibition of heparanase and also the modulation ofMMP-9 production . in clinical evaluation, sulodexide was able to restore endothelial glycocalyx and vascular permeability in patients with type 2 diabetes.